Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133292 | 1.00 | P4HB (0.68) | P4HBPKMNPSR1KDM4EALDH1A1 | |
| SCHEMBL4407110 | 0.88 | P4HB (0.68) | P4HBALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL11222093 | 0.88 | P4HB (0.68) | P4HBALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18098004 | 0.87 | P4HB (0.68) | P4HBKDM4EALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL14406520 | 0.87 | P4HB (0.68) | P4HBKDM4EALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL24411012 | 0.87 | P4HB (0.62) | P4HBBCHEGRIN2DGRIN3BGRIN1 | |
| SCHEMBL29496462 | 0.87 | P4HB (0.62) | P4HBBCHEGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1926761 | 0.87 | P4HB (0.62) | P4HBBCHEGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1926762 | 0.87 | P4HB (0.62) | P4HBBCHEGRIN2DGRIN3BGRIN1 | |
| SCHEMBL14594290 | 0.86 | P4HB (0.66) | P4HBKDM4EALDH1A1SMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021115188-A1 | HISTONE DEACETYLASE, AND PROTEASOME DUAL-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东大学 | 2021-06-17 | — | — | WO | disclosed |
| CN-110950897-B | Histone deacetylase, protease double-target inhibitor, preparation method and application thereof | 山东大学 | 2021-05-28 | — | — | CN | disclosed |
| CN-110950897-A | Histone deacetylase, protease double-target inhibitor, preparation method and application thereof | 山东大学 | 2020-04-03 | — | — | CN | disclosed |
| US-9540338-B2 | Substituted cinnamic acid amides for treating pain | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2940003-A1 | CINNAMIC ACID AMIDE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| EP-0201823-B1 | NOVEL INTERMEDIATES FOR THE PRODUCTION OF PHARMACEUTICALS | LILLY INDUSTRIES LIMITED (GB) | 1990-12-05 | — | — | EP | disclosed |
| US-4963578-A | LEUKOTRIN ANTAGONISTS; ANTIALLERGENS | LILLY INDUSTRIES LIMITED (GB) | 1990-10-16 | — | — | US | disclosed |
| US-RE33300-E | LEUKOTRIENE ANTAGONISTS; ANTIALLERGENS | ELI LILLY AND COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| US-4948796-A | TREATING CEREBO-VASCULARE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4845110-A | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1989-07-04 | — | — | US | disclosed |
| EP-0134111-B1 | ARALIPHATIC SULPHIDES,SULPHONES AND SULPHOXIDES AND THEIR PHARMACEUTICAL USE | Lilly Industries Limited (GB) | 1988-12-07 | — | — | EP | disclosed |
| EP-0235452-A2 | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1987-09-09 | — | — | EP | disclosed |
| US-4665189-A | LEUKOTRIENE ANTAGONISTS | LILLY INDUSTRIES LIMITED (GB) | 1987-05-12 | — | — | US | disclosed |
| EP-0201823-A2 | Novel intermediates for the production of pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1986-11-20 | — | — | EP | disclosed |
| EP-0134111-A1 | Araliphatic sulphides,sulphones and sulphoxides and their pharmaceutical use | Lilly Industries Limited (GB) | 1985-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | P4HB 4227/4885PKM 2399/4885NPSR1 1898/4885 |
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | OPRL1, TRPV1, TRPA1 | P4HB 3460/4885PKM 3882/4885NPSR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.